STOCK TITAN

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
Defence Therapeutics Inc. (OTCPK: DTCFF): Oncology drugs market growth is driven by rising cancer prevalence, new drug launches, and research activities. The global oncology drugs market size is projected to grow from USD 205.52 billion in 2023 to USD 484.32 billion by 2030, exhibiting a CAGR of 13.0%. Defence Therapeutics submitted an Investigational New Drug (IND) application for AccuTOX®, an injectable anticancer molecule, with potential to combat solid tumors. The company aims to advance AccuTOX® into clinical trials, with the primary objective of identifying therapeutic dosing range for co-administration with Opdulag®, a BMS product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Merck (MRK) announces positive opinion from CHMP for approval of KEYTRUDA in combination with gemcitabine and cisplatin for the first-line treatment of biliary tract carcinoma, based on Phase 3 KEYNOTE-966 trial results, showing significant improvement in overall survival (OS) compared to chemotherapy alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Rhea-AI Summary
MRK: Merck's CFO to Speak at Jefferies London Healthcare Conference on Nov. 16, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
Rhea-AI Summary
Merck (NYSE: MRK) announced that Jannie Oosthuizen, president, Human Health U.S., will participate in a fireside chat at the UBS BioPharma Conference on Nov. 8, 2023, at 12:00 p.m. EST. The presentation will be available via live audio webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
-
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has been approved by the FDA for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. The approval was based on the Phase 3 KEYNOTE-966 trial, which showed a 17% reduction in the risk of death when KEYTRUDA was combined with gemcitabine and cisplatin compared to chemotherapy alone. Median overall survival was 12.7 months for KEYTRUDA plus chemotherapy versus 10.9 months for chemotherapy alone. This marks the sixth gastrointestinal cancer indication for KEYTRUDA in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
fda approval
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy. The Phase 3 KEYNOTE-564 trial demonstrated a significant disease-free survival benefit and met its key secondary endpoint of OS compared to placebo. The safety profile of KEYTRUDA was consistent with previous studies. Results will be presented at a medical meeting and submitted to regulatory authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary
Merck announces financial results for Q3 2023, with total worldwide sales of $16.0 billion, an increase of 7% from Q3 2022. Key highlights include the growth of KEYTRUDA sales by 17% to $6.3 billion and the collaboration agreement with Daiichi Sankyo for three clinical-stage ADC candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
earnings
-
Rhea-AI Summary
Sarah M. Aiosa, SVP and president, Latin America, has been recognized as one of The Association of Latino Professionals for Americas' 2023 Most Powerful Latinas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Merck announced positive results from the Phase 3 KEYNOTE-A39 trial, showing that KEYTRUDA plus enfortumab vedotin significantly improved overall survival and progression-free survival in patients with urothelial carcinoma. The combination therapy reduced the risk of death by 53% and the risk of disease progression or death by 55% compared to chemotherapy. These results have the potential to change the treatment paradigm for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Merck & Co Inc

NYSE:MRK

MRK Rankings

MRK Stock Data

334.18B
2.53B
0.07%
78.61%
0.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.